Free newsletter
The Peptide Research Digest
Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.
Prices, providers, and published evidence — tracked independently, never an affiliate code. Get research updates as the data grows.
Free · occasional research updates only · unsubscribe in one click
Already a member? Sign in
Peptide Profile
Mounjaro · Zepbound · Dual GLP-1 · GLP-1/GIP
Tirzepatide is a once-weekly injectable dual agonist of GLP-1 and GIP receptors, FDA approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). Clinical trials demonstrate weight reductions exceeding those seen…
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Tirzepatide is a once-weekly injectable dual agonist of GLP-1 and GIP receptors, FDA approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). Clinical trials demonstrate weight reductions exceeding those seen with semaglutide in head-to-head comparisons. Compounded formulations are offered by telehealth and functional medicine providers across the US. It represents the current clinical benchmark for pharmacological weight management. Mechanism of action: Tirzepatide activates two incretin receptors simultaneously — the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GLP-1 activation suppresses appetite, slows gastric emptying, and potentiates insulin secretion; GIP activation independently stimulates insulin release and may reduce some of the GI side effects associated with pure GLP-1 agonism. The dual mechanism produces greater appetite suppression and metabolic improvement than either receptor pathway alone, which accounts for the superior weight reduction seen in clinical trials relative to semaglutide. Clinical evidence: The SURMOUNT trial program established tirzepatide's weight reduction profile. SURMOUNT-1 (2022) found a mean weight reduction of 22.5% over 72 weeks at the highest dose (15mg/week) vs 2.4% with placebo — the largest mean weight reduction reported for any approved pharmacological intervention at that time. SURMOUNT-5 (2024) was a direct head-to-head comparison with semaglutide 2.4mg: tirzepatide 10mg and 15mg produced significantly greater weight reductions (20.2% vs 13.7% for semaglutide). The SURPASS trials established cardiometabolic and glycaemic benefits in T2D contexts. Tirzepatide vs semaglutide: Tirzepatide's dual GIP+GLP-1 mechanism produces greater mean weight reductions in trials but also a distinct side effect profile. GI tolerability may be slightly better than pure GLP-1 agonism for some users due to the GIP component, though nausea and gastrointestinal symptoms remain the most common adverse effects. Semaglutide has a larger body of long-term safety data; tirzepatide has superior head-to-head efficacy data. Prescribers select between them based on clinical context, cost, access, and patient response history. Access and regulatory status: Tirzepatide requires a prescription from a licensed provider. Branded formulations (Mounjaro, Zepbound) are available at licensed pharmacies. Compounded tirzepatide has been subject to evolving FDA guidance around shortage status; access through compounding channels varies by jurisdiction and regulatory period. Providers offering tirzepatide-based programs are indexed in the PeptideBase directory.
Commonly researched in the context of
Population research notes
These signals reflect research interest areas, not treatment indications.
Compound & timing
Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.
based on 13 studies · 3 RCTs · most recent 2026
FDA-approved as Mounjaro (diabetes) and Zepbound (obesity). Prescription only.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
13 sources cited · 3 strong · 10 moderate
3 RCTs · 7 Cohorts · 3 Reviews
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Lancet · 2023
Research found that tirzepatide 15 mg reduced mean body weight by 14.7% over 72 weeks compared with 3.2% for placebo in adults with obesity and type 2 diabetes, with more than 79% of participants achieving at least 5% weight reduction.
Tirzepatide Once Weekly for the Treatment of Obesity
New England Journal of Medicine · 2022
In the 72-week phase 3 SURMOUNT-1 trial, tirzepatide 15 mg reduced mean body weight by 20.9% compared with 3.1% for placebo in adults with obesity, with 57% of participants achieving at least 20% weight reduction.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
New England Journal of Medicine · 2021
In this 40-week phase 3 trial, tirzepatide at all three doses produced significantly greater reductions in HbA1c and body weight compared with semaglutide 1 mg in adults with type 2 diabetes, with the highest dose achieving approximately 5.5 kg additional weight reduction over semaglutide.
Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies.
Dermatol Surg · 2026
# Summary Research found that while glucagon-like peptide-1 receptor agonists—including tirzepatide—have not yet been proven to directly affect lipedema progression, translational evidence suggests these therapies may influence inflammatory and fibrotic pathways relevant to the condition and could potentially serve as adjunctive treatment options. This study demonstrated that very limited direct patient evidence currently exists, with only a small case series showing improvements in pain and limb volume, indicating that further research is needed to establish the clinical role of these therapies in lipedema management.
A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model.
Biomed Pharmacother · 2026
Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes.
Commun Med (Lond) · 2026
Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes.
Commun Med (Lond) · 2026
A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model.
Biomed Pharmacother · 2026
Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study.
Diabetes Ther · 2026
# Summary Research found that tirzepatide demonstrated significant effectiveness in real-world clinical practice among Japanese patients with type 2 diabetes, producing meaningful reductions in both blood sugar control (HbA1c) and body weight over a 24-week period. This study demonstrated that patients who had not previously received GLP-1 receptor agonist therapy showed greater improvements in blood sugar levels, and that baseline blood sugar levels—rather than body mass index—were the primary predictor of treatment response.
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Hair Loss: Clinical Evidence and Proposed Mechanisms.
Dermatol Surg · 2026
# Summary Research found that glucagon-like peptide-1 receptor agonists (GLP-1RAs), including tirzepatide, are associated with hair loss conditions such as telogen effluvium and androgenic alopecia, with risk potentially increasing with longer treatment duration, greater weight loss, and higher doses. This study demonstrated that while proposed mechanisms include weight loss-related changes and hormonal influences, the evidence remains conflicting, and dermatology practitioners should monitor patients receiving GLP-1RA therapy for these potential adverse effects.
Cardiovascular Risk Reduction With Tirzepatide, a Dual GIP/GLP-1 Agonist, in Patients With Type 2 Diabetes Mellitus.
J Lipid Atheroscler · 2026
# Summary Research found that tirzepatide, a dual GIP/GLP-1 receptor agonist, produced significant reductions in blood sugar levels (hemoglobin A1c) and body weight in patients with type 2 diabetes, while also improving lipid parameters and lowering blood pressure. This study demonstrated that these cardiovascular and metabolic benefits occurred without increasing serious hypoglycemia risk, with adverse events primarily consisting of mild gastrointestinal symptoms comparable to other GLP-1 receptor agonists.
DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model.
Mol Ther Nucleic Acids · 2026
# Summary Research found that using MYO Technology—a DNA-based delivery platform administered via intramuscular injection—enabled incretin receptor agonists to produce sustained weight loss and glucose control in obesity models with effects lasting over one year from a single administration. This study demonstrated that engineering these agonists to cross the blood-brain barrier further enhanced treatment efficacy, potentially reducing the frequent dosing burden associated with currently available incretin receptor agonist medications.
Marked improvement in severe hidradenitis suppurativa following tirzepatide therapy: a case report.
Int J Womens Dermatol · 2026
Contraindications below are derived from the compound’s FDA label. Educational only — not medical advice.
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Absolute contraindications
Warnings & cautions
Source: FDA label
Common monitoring markers in research protocols
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Compare
VSTirzepatide
Median tested purity
99.8%
Median tested purity of 99.8% across 24 verified third-party lab COAs (interquartile range 99.6%–99.8%), as reported by the independent testing labs below. PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Tirzepatide - 20 · Lot TRZ20-14 · Jul 8, 2026
99.9%
Purity
GLP-2T 10mg · Lot V2087944195 · Jul 2, 2026 · View source COA
100.0%
Purity
Tirzepatide · Jun 29, 2026 · View source COA
99.6%
Purity
Tirzepatide · Jun 29, 2026 · View source COA
99.7%
Purity
GLP-TZ 30mg · Lot Clear Pink Cap · Jun 29, 2026 · View source COA
99.1%
Purity
Tirzepatide · Jun 29, 2026 · View source COA
99.6%
Purity
Tirzepatide · Jun 23, 2026 · View source COA
99.8%
Purity
Tirzepatide · Jun 22, 2026 · View source COA
99.7%
Purity
Tirzepatide · Jun 19, 2026 · View source COA
99.6%
Purity
Tirzepatide · Jun 16, 2026 · View source COA
99.0%
Purity
GLP-2T 5mg · Lot C225H348N48O68 · Jun 13, 2026 · View source COA
99.9%
Purity
Tirzepatide · Jun 10, 2026 · View source COA
98.8%
Purity
Tirzepatide · Jun 9, 2026 · View source COA
99.5%
Purity
TRZ - 60mg · Lot TRZ60-04 · Jun 5, 2026
99.9%
Purity
Tirzepatide · Jun 2, 2026 · View source COA
99.5%
Purity
Tirzepatide · May 27, 2026 · View source COA
99.5%
Purity
Tirzepatide · May 18, 2026 · View source COA
99.8%
Purity
TRZ 20MG - 20mg · Lot TRZ20-13 · May 6, 2026
99.9%
Purity
TRZ - 40mg · Lot TRZ40-14 · May 6, 2026
99.9%
Purity
TRZ - 30mg · Lot TRZ30-12 · May 6, 2026
99.9%
Purity
Tirzepatide · Apr 28, 2026 · View source COA
99.8%
Purity
Tirzepatide · Apr 28, 2026 · View source COA
99.9%
Purity
Tirzepatide · Apr 17, 2026 · View source COA
99.8%
Purity
Tirzepatide · Apr 15, 2026 · View source COA
99.9%
Purity
Tirzepatide · Apr 14, 2026 · View source COA
99.8%
Purity
Tirzepatide · Apr 14, 2026 · View source COA
99.8%
Purity
Tirzepatide · Apr 14, 2026 · View source COA
99.8%
Purity
Tirzepatide · Apr 14, 2026 · View source COA
99.8%
Purity
Tirzepatide · Mar 25, 2026 · View source COA
99.9%
Purity
Tirzepatide · Mar 6, 2026 · View source COA
99.8%
Purity
Tirzepatide · Feb 16, 2026 · View source COA
99.9%
Purity
Tirzepatide · Jan 21, 2026 · View source COA
99.9%
Purity
Tirzepatide · Jan 13, 2026 · View source COA
99.2%
Purity
TIRZEPATIDE · Lot 251110TZ203 · Nov 13, 2025
99.8%
Purity
Tirzepatide · Lot FP25-1020 · Oct 1, 2025
99.8%
Purity
Tirzepatide · Lot FP25-1019 · Oct 1, 2025
99.8%
Purity
Tirzepatide · Lot FP25-1017 · Oct 1, 2025
99.8%
Purity
Tirzepatide 10mg · Lot TIR 1007232025-09 · Jul 27, 2025 · View source COA
99.9%
Purity
Tirzepatide · Jul 22, 2025 · View source COA
99.8%
Purity
Tirzepatide · Jul 22, 2025 · View source COA
99.8%
Purity
Tirzepatide · Sep 30, 2024 · View source COA
99.7%
Purity
PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product. Verified results come from an independent third-party lab database lookup. Vendor-published results are reported by the vendor itself and have not been independently verified by PeptideBase or a third-party lab.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Self-reported, anecdotal experiences aggregated from public Reddit discussions — community sentiment, not clinical evidence or medical advice.
Outcome distribution
Outcomes by goal · improved % · reports
Side effects people mention
Counts are mentions across reports, not incidence rates.
Most reported
What they wish they'd known
Based on 468 community reports · Updated
Tirzepatide is a once-weekly injectable dual agonist of GLP-1 and GIP receptors, FDA approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). Clinical trials demonstrate weight reductions exceeding those seen with semaglutide in head-to-head comparisons.
Fat Loss.
Research on Tirzepatide primarily documents effects related to Fat Loss. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Tirzepatide include Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), Known hypersensitivity to the drug or excipients. 7 additional considerations are noted in the safety profile above. This is educational information only — consult a qualified healthcare professional before use.
For Tirzepatide, its FDA status is FDA-approved, and it is available by prescription. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
477 providers in the directory currently offer Tirzepatide.
Across 11 research vendors tracked on PeptideBase, Tirzepatide has a median price of about $6.80 per mg, typically ranging $4.56–$8.94 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.
Research found that tirzepatide 15 mg reduced mean body weight by 14.7% over 72 weeks compared with 3.2% for placebo in adults with obesity and type 2 diabetes, with more than 79% of participants achieving at least 5% weight reduction.
Tirzepatide is featured in the following research stacks on PeptideBase: AOD-9604 + Tirzepatide: Advanced Body Composition.
Price per mg varies by quantity, vendor type, and formulation. Research use only.
Data verified July 2026 · Tirzepatide price intelligence
+advitam®
Active Pain Relief & Wellness
Advanced Age Management
Advantage Wellness Center
Affinity Whole Health
Ageless Beauty Rx
AMAVA Regenerative Medicine Peoria-Glendale AZ
AntiAging MD
Asymmetric Health
Atlanta Men's Clinic
Commonly stacked with
Stay updated on verified Tirzepatide providers
New verified providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Tirzepatide Dose Calculator
Calculate exact draw volume and doses per vial for Tirzepatide.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Tirzepatide — Per-mg Price Benchmark. Retrieved July 22, 2026, from https://peptidebase.io/peptides/tirzepatide